HTX-011 in Combination with Multimodal Analgesic Regimen Minimized Severe Pain and Opioid Use after Total Knee Arthroplasty in an Open-Label Study

• Published in: The Journal of knee surgery Vol. 36; no. 9; p. 925
• Main Authors: Lee, Gwo-Chin, Berkowitz, Richard, Hacker, Scott, Hu, Jia, Rechter, Alan
• Format: Journal Article
• Language: English
• Published: Germany 01.07.2023
• Subjects: Acetaminophen - therapeutic use; Analgesics - therapeutic use; Analgesics, Opioid; Anesthetics, Local - therapeutic use; Arthroplasty, Replacement, Knee - adverse effects; Bupivacaine - therapeutic use; Celecoxib - therapeutic use; Humans; Meloxicam - therapeutic use; Opioid-Related Disorders; Pain, Postoperative - drug therapy; Pain, Postoperative - etiology
• ISSN: 1938-2480
• DOI: 10.1055/s-0042-1747945

Total knee arthroplasty (TKA) can be associated with significant postoperative pain despite multimodal analgesic (MMA) protocols, and most patients require the use of opioids postoperatively. HTX-011 is a dual-acting local anesthetic containing bupivacaine and low-dose meloxicam in an extended-release polymer. In a prior randomized controlled trial (RCT), HTX-011 reduced pain and opioid use through 72 hours after TKA compared with bupivacaine hydrochloride. This open-label study (NCT03974932) evaluated the efficacy and safety of HTX-011 combined with an MMA regimen in patients undergoing TKA under spinal anesthesia. All patients received intraoperative HTX-011 (400 mg bupivacaine/12 mg meloxicam) in combination with an MMA regimen consisting of preoperative acetaminophen, celecoxib, and pregabalin and postoperative acetaminophen and celecoxib until discharge. Opioid rescue was allowed upon patient request for additional pain control. Pain scores, opioid consumption, discharge readiness, and adverse events were recorded. Fifty-one patients were treated. Compared with the prior RCT, HTX-011 with this MMA regimen further lowered pain scores and reduced opioid use. Mean patient-reported pain scores remained in the mild range, and 82% of patients or more did not experience severe pain at any individual time point through 72 hours after surgery. Mean total opioid consumption was low over 72 hours: 24.8 morphine milligram equivalents (1-2 tablets of oxycodone 10 mg/day). Approximately 60% of patients were ready for discharge by 12 hours, and 39% were discharged without an opioid prescription and did not call back for pain management. The treatment regimen was well tolerated, and no added risk was observed with the addition of MMA. HTX-011 with an MMA regimen reduced postoperative pain and opioid use following TKA.